Moderna's Next Gen COVID Vaccine Meets Primary Goal In Late-Stage Trial
Portfolio Pulse from Vandana Singh
Moderna Inc (NASDAQ:MRNA) announced that its next-generation COVID-19 vaccine, mRNA-1283, met the primary endpoints in its Phase 3 trial, showing a higher immune response than its current vaccine, mRNA-1273.222. The vaccine demonstrated effectiveness against the Omicron BA.4/BA.5 and original virus strains, particularly in individuals over 65. mRNA-1283 has a similar safety profile to Moderna's approved vaccines and offers benefits in storage and accessibility. Detailed Phase 3 data will be shared at Moderna's Vaccines Day and upcoming conferences. MRNA shares dropped 1.36% to $108.88.
March 26, 2024 | 4:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Moderna's mRNA-1283 vaccine shows superior immune response in Phase 3 trials, particularly benefiting those over 65. Shares fell 1.36% to $108.88.
The announcement of mRNA-1283 meeting its primary endpoints in Phase 3 trials is significant, indicating a strong potential for market success and public health impact. However, the immediate market reaction was negative, with MRNA shares dropping 1.36%. This could be due to various factors, including market expectations, overall market conditions, or investor sentiment towards biotech investments. The short-term impact is negative, but the long-term outlook could be positive as the vaccine progresses towards approval and commercialization.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100